CLOs on the Move

Enzyvant

www.enzyvant.com

 
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.enzyvant.com
  • 90 Broadway Suite 204
    Cambridge, MA USA 02142
  • Phone: 617.704.9385

Executives

Name Title Contact Details
Tamara Joseph
General Counsel Profile

Similar Companies

ProThera Biologics (Main)

ProThera Biologics, LLC (Main) is a East Providence, RI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Ibis Biosciences a Division of Abbott

Ibis Biosciences a Division of Abbott is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lineage Cell

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage`s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage`s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer.

Knopp Neurosciences

Knopp Neurosciences is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

A W Research Laboratories

A W Research Laboratories is a Brainerd, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.